Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Langerhans cell histiocytosis (LCH) is a rare disease with limited treatment options. We present a case involving a 57-year-old woman afflicted with an isolated LCH bone osteolytic lesion. A single bisphosphonate infusion significantly alleviated pain, and follow-up scans via CT, PET-CT, and MRI revealed a substantial recalcification of the lesion. Conducting an extensive literature review, we identified 46 cases documenting the efficacy of bisphosphonates in the context of LCH. These findings have raised interest in bisphosphonate infusion as a simple therapeutic alternative in similar situations, with benefits in terms of bone recalcification and pain control for individuals with LCH.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11032215 | PMC |
| http://dx.doi.org/10.1093/jbmrpl/ziae043 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Perioperative Denosumab Versus Bisphosphonates for MIDLF Surgery in Patients With Osteopenia: A Short-Term Prospective Cohort Study.
Global Spine J
September 2025
Department of Orthopaedic, Peking University First Hospital, Beijing, China.
Study DesignProspective Cohort Study.ObjectiveTo compare the effectiveness and safety of perioperative denosumab, bisphosphonates, and a control group in promoting lumbar fusion after midline lumbar fusion (MIDLF) surgery in patients with osteopenia or osteoporosis.MethodsThis prospective cohort study enrolled 54 patients with osteopenia or osteoporosis undergoing MIDLF surgery.
View Article and Find Full Text PDFThe relationship between osteoporosis treatment history and receipt of a second zoledronic acid dose.
Osteoporos Int
September 2025
Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada.
Unlabelled: We examined characteristics of patients in Ontario, Canada, initiating publicly funded zoledronic acid for osteoporosis from 2006 to 2021. Most patients had prior osteoporosis treatments, with those previously using oral bisphosphonates more likely to receive a second dose. Understanding treatment decisions and patient beliefs is key for future research.
View Article and Find Full Text PDFAcute Myocarditis Following Zoledronic Acid Infusion: Cardiac MRI Diagnosis of a Rare Cardiotoxic Event with Contextual Literature Review.
Diagnostics (Basel)
August 2025
Department of Radiology, Soroka Medical Center, Ben Gurion University, Beer Sheva 84105, Israel.
Background and Clinical Significance: Zoledronic acid (ZA) is a widely used bisphosphonate for the prevention of skeletal-related events in patients with metastatic bone disease. While it is generally well tolerated, rare immune-mediated complications may be underrecognized. To date, myocarditis has not been reported in association with ZA.
View Article and Find Full Text PDFZoledronic acid-induced acute psychiatric disorder.
Osteoporos Int
July 2025
Department of Geriatrics, The Third Hospital of Mianyang, Sichuan Mental Health Center, Jiannan Road, Youxian District, Mianyang, Sichuan, China.
As a bisphosphonate drug, zoledronic acid is widely used in the treatment of osteoporosis, hypercalcemia, Paget's disease, and solid malignant tumors. Common adverse reactions include acute-phase responses such as myalgia, fatigue, arthralgia, and fever, while psychiatric disorders have been infrequently reported. This paper presents a case of acute psychiatric disorder in an osteoporotic patient following intravenous infusion of zoledronic acid for the first time, underscoring the necessity of clinical vigilance regarding such rare adverse reactions during treatment.
View Article and Find Full Text PDFComparing the time spent in clinic by patients receiving, subcutaneous and intravenous formulations of cancer drugs: A pilot study.
J Cancer Policy
September 2025
University of Minnesota, Minneapolis, MN, USA. Electronic address:
Background: Subcutaneous (SC) formulations of cancer-directed and supportive care drugs are associated with time savings relative to their intravenous (IV) formulations in clinical trials, but it is unclear if these time savings apply in routine practice.
Methods: We performed a retrospective study of adults with breast cancer treated at a single U.S.